In Brief: Investigational device Medicare coverage
This article was originally published in The Gray Sheet
Executive Summary
Investigational device Medicare coverage: FDA categorizes 1,031 out of 1,101 (93.6%) devices involved in ongoing investigational device exemption-approved clinical trials as "non-experimental" and thus eligible for Medicare reimbursement under a final rule published by HCFA in the Sept. 19 Federal Register ("The Gray Sheet" Sept. 18, p. 2). Under the rule, which went into effect Nov. 1, FDA is forwarding to HCFA the determinations as to whether devices used in IDE trials are "experimental" or "non-experimental." To ensure sponsors' confidentiality, FDA is releasing only IDE numbers along with a categorization decision. However, InterVentional Technologies announced Nov. 1 that its Barath surgical dilatation balloon catheter, which is involved in trials comparing restenosis rates with conventional percutaneous transluminal coronary angioplasty ("The Gray Sheet" July 18, 1994, In Brief), has been categorized as non-experimental...
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.